A Long-term Study of KP-001 in patients with vascular malformation including venous malformation, lymphatic malformation, and Klippel-Trenaunay Syndrome (Phase III)

Hideki Kawabata0 个研究点目标入组 50 人开始时间: 2023年8月3日最近更新: 2023年10月17日

适应症

试验速览

阶段: 3 期
状态: 招募中
发起方
入组人数: 50

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 2age old 至 ot applicable（—）
性别: All

入选标准

•1. Patients who complete the 52-week treatment period in the Phase III confirmatory study and are diagnosed as requiring continuation of investigational drug beyond 52 weeks.
•1. Patient is at least 2 years of age at time of consent
•2. Diagnosed as one of the following - ISSVA classification of Common VM, Common (cystic) LM (including combined type mainly consisting of VM or LM)
•- Klippel-Trenaunay Syndrome
•- Megalencephaly-capillary malformation-polymicrogyria
•- Lymphangiomatosis
•- Lymphangioleiomyomatosis in Gorham-Stout disease
•- Lymphangiectasia
•- Familial VM cutaneo-mucosal
•- CLOVES syndrome
•- CLAPO syndrome
•- Proteus syndrome
•- Diseases other than those listed above that are associated with PIK3CA-related overgrowth spectrum
•- Blue rubber bleb nevus syndrome
•3. Diagnosed as pain, bleeding, disfigurement, inflammation such as cellulitis, etc., and judged to be symptomatic
•4. Diagnosed as refractory because resection is not curative, resection is difficult, or for other reasons
•1. Patients who complete the 24-week treatment period in the Phase II study and are diagnosed as requiring the administration of investigational drug and wish to resume the administration of it

排除标准

•1. Diagnosed as having diabetes mellitus (type I or II) or a disease with abnormal glucose metabolism (glycogen storage disease, hypergalactosemia, primary lactose intolerance, etc.) and poor control of the disease
•2. Diagnosed as having hepatic or renal impairment
•3. Patients with ischemic heart disease, arrhythmia, or heart failure (NYHA III or IV degree) diagnosed as inadequately controlled
•4. Patients who wear orthodontic appliances, cochlear implants, etc., which may affect MRI imaging.
•1. Diagnosed as having diabetes mellitus (type I or II) or a disease with abnormal glucose metabolism (glycogen storage disease, hypergalactosemia, primary lactose intolerance, etc.) and poor control of the disease
•2. Diagnosed as having hepatic or renal impairment
•3. Patients with ischemic heart disease, arrhythmia, or heart failure (NYHA III or IV degree) diagnosed as inadequately controlled
•4. Patients who are unable to take drug orally
•5. Patients who wear orthodontic appliances, cochlear implants, etc., which may affect MRI imaging. (Only for subjects whose target lesions are assessed by MRI imaging)
•6. Patients with target lesion infection requiring treatment within 28 days prior to the date of consent
•7. Patients who have undergone invasive treatment, including sclerotherapy or laser therapy, for the target lesion within 84 days prior to the date of consent
•8. Patients who have used other PI3Ka inhibitors or Sirolimus within 84 days prior to the date of consent
•1. Diagnosed as having diabetes mellitus (type I or II) or a disease with abnormal glucose metabolism (glycogen storage disease, hypergalactosemia, primary lactose intolerance, etc.) and poor control of the disease
•2. Diagnosed as having hepatic or renal impairment
•3. Patients with ischemic heart disease, arrhythmia, or heart failure (NYHA III or IV degree) diagnosed as inadequately controlled
•4. Patients who are unable to take drug orally
•5. Patients who have undergone invasive treatment, including sclerotherapy or laser therapy, for the target lesion within 84 days prior to the date of consent
•6. Patients who have used other PI3Ka inhibitors or Sirolimus within 84 days prior to the date of consent

研究者

发起方

Hideki Kawabata

相似试验

已完成

3 期

A multicentre, long-term trial of KN01 in patients with MELAS

JPRN-UMIN000019195Kawasaki Medical School Hospital9

进行中（未招募）

不适用

Determinants of vascualr dysfunction in chronic kidney disease

ACTRN12605000235606Pfizer105

进行中（未招募）

1 期

Phase II Study of ZK 219477 in patients with recurrent glioblastoma

EUCTR2006-001659-37-GBEuropean Organisation for Research and Treatment of Cancer

进行中（未招募）

1 期

Phase II Study of ZK 219477 in patients with recurrent glioblastomaPhase II study of ZK 219477 in patients with recurrent glioblastoma.MedDRA version: 8.1Level: LLTClassification code 10018336Term: Glioblastoma

EUCTR2006-001659-37-DEEuropean Organisation for Research and Treatment of Cancer

进行中（未招募）

1 期

EUCTR2006-001659-37-NLEuropean Organisation for Research and Treatment of Cancer